Document:

EX-10.24

 Exhibit 10.24 

AMENDMENT NO. 1 
 TO THE

 PATENT AND TECHNOLOGY LICENSE AGREEMENT 

This is AMENDMENT NO. 1 effective this 1st day of September, 1996, (“EFFECTIVE
AMENDMENT NO. 1 DATE”) to the Patent and Technology License Agreement dated July 20, 1994 (hereinafter referred to as the “AGREEMENT”), by and between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to
as “MDA”), located at Houston, Texas, and which is a component institution of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter referred to as “SYSTEM”) which is governed by a BOARD OF REGENTS (hereinafter referred to as
“BOARD”) and INTROGEN THERAPEUTICS, INC,. located at 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (hereinafter referred to as “LICENSEE”). 

RECITALS 
 A. BOARD is the
owner of the PATENT AND TECHNOLOGY RIGHTS of the invention(s) listed in ATTACHMENT A hereto (“INVENTION(s)”). 
 B. LICENSEE is a
company interested in the development and commercialization of new technologies directed to the treatment of cancer, and other threatening diseases, to which end LICENSEE, MDA and BOARD entered into the AGREEMENT noted hereinabove. 

C. LICENSEE wishes to add the INVENTION(s) to its rights and obligations under the AGREEMENT. 

D. BOARD wishes to grant LICENSEE rights to the INVENTION(s) under the AGREEMENT to promote its practical development for the benefit of the
MDA’s patients and for the benefit of the people of the state of Texas. 
 E. The definitions set forth in the AGREEMENT shall apply in
this AMENDMENT NO. 1, except to the extent that a definition herein is specific to this AMENDMENT NO. 1. 
 NOW, THEREFORE, in
consideration for the mutual covenants contained herein, the sufficiency of which is hereby acknowledged the parties hereby agree to the following: 

 AMENDED TERMS 

1. Attachment A to the AGREEMENT is hereby amended by adding to the LICENSED SUBJECT MATTER thereof the INVENTION(s) listed in Schedule A
of this Amendment 
 2. In addition to the reimbursements for patent expenses provided for under the AGREEMENT and all other amendments
thereto, LICENSEE shall reimburse MDA within thirty (30) days of the EFFECTIVE DATE of this AMENDMENT NO. 1 for all outstanding and unreimbursed patent expenses related to the INVENTION(s) and shall further reimburse MDA for all future and
continuing patent expenses for the INVENTION(s) pursuant to Article 4.1(a) of the AGREEMENT for the term of the AGREEMENT, pursuant to invoicing by MDA. 

OTHERWISE, the terms and provisions of the original AGREEMENT thereto shall remain in full force and effect, provided, however, that in the
event of a conflict in the terms and conditions between this AMENDMENT NO. 1 and the AGREEMENT, the terms and conditions of the AGREEMENT shall prevail. 

IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to execute this AMENDMENT NO. 1. 

 

									
	 THE UNIVERSITY OF TEXAS

M.D. ANDERSON CANCER CENTER
	 		 	 BOARD OF REGENTS OF THE

UNIVERSITY OF TEXAS SYSTEM

					
	By:	 	 /s/ David J. Bachrach
	 		 	By:	 	 /s/ Charles B. Mullins, M.D.

		 	 David J. Bachrach
 Executive Vice
President
 for Administration and Finance
	 		 		 	 Charles B. Mullins, M.D.

Chancellor

			
	APPROVED AS TO CONTENT	 		 	APPROVED AS TO FORM
					
	By:	 	 /s/ William J. Doty
	 		 	By:	 	 /s/ Dudley R. Dobie, Jr.

		 	 William J. Doty
 Director, Technology
Development
	 		 		 	 Dudley R. Dobie, Jr.
 Manager,
Intellectual Property

				
	INTROGEN THERAPEUTICS, INC.	 		 		 	
					
	By:	 	 /s/ David G. Nance
	 		 		 	
		 	 David G. Nance
 President
	 		 		 	

  
 2 

 SCHEDULE A 

Patent and Technology rights for U.S. and Foreign Patent Application entitled: 

“Diminishing Viral Gene Expression by Promoter Replacement” patent has not been filed yet (MDA Ref: ID96-47) 

“Alteration of Imnunogenicity Through Chemical Modification of Viral Vectors for in vivo Gene Therapy”, patent has not been filed yet
(MDA Ref: INGN:027) 
 “2-methoxyestradiol Induced Apoptosis in Human Lung Cancer Cells”, US Patent filed July 30, 1996 (MDA
Ref: INGN:024) 
 “Clinical Protocol for Modification of Tumor Suppressor Gene Expression and Induction of Apoptosis in Head and Neck
Squamous Cell Carcinoma (HNSCCI) with an Adenovirus Vector Expression Wildtype p53”, US Serial No. 60/007810, filed November 30, 1995 (MDA Ref: INGN:022) 

“Inhibition of Tumor Cell Growth by p16(ink4) Mediated by an Adenovirus Vector” US Serial No. 502,881, filed July 17, 1995,
PCT filed July 17, 1996 (MDA Ref: INGN:016) 
 “Inhibition of Tumor Cell Growth by an anti-Kras Adenovirus”, US Serial
No. 550959, filed October 31, 1995 (MDA Ref: INGN:015) 
 “Modification of Mutated p53 Gene in the Tumor by Retroviral
Delivery of Ribozyme A, a Therapeutic Strategy for Cancer” US Serial No. 523,030, filed September 1, 1995 (MDA Ref: UTSC:467) 

“C-Cam Recombinant Adenovirus” US Serial No. 494,622, filed June 23, 1995, PCT Serial No. US96/10696 filed June 23,
1996, (MDA Ref: UTSC:464) 
 “The Use of Cisplatin and Other Chemicals to Enhance the Transcution of Cancer Cells” patent has not
been filed yet (MDA Ref: UTSC:470) 
 “A Rapid Test for Determining the Amount of Functionally Inactive Gene in a Gene therapy Vector
Preparation” US Serial No. 390,887, filed February 17, 1995, PCT Serial No. US/02042, filed February 14, 1996, (MDA Ref: UTSC:458) 

“The Use of Epidermal Growth Factor and other Ligands for the Targeting of Genetic Material to Lung Cancer Cells” US Serial
No. 410,526, filed March 24, 1995, PCT Serial No. US96/04017, filed March 25, 1996 (MDA Ref: UTSC:434) 
 “Adenoviral
Helper Vector System” US Serial No. 423,573, filed April 17, 1995, PCT Serial No. US96/05310, filed April 17, 1996 (MDA Ref: UTSC:438) 

“Inhibition of Cell Growth by an Anti-Proliferative Factor”, US Patent Application filed August 23, 1996 (MDA Ref: ID97-02) 

  
 3EX-10.25

 Exhibit 10.25 

CONFIDENTIAL TREATMENT REQUESTED 

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN 

SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION 

AMENDMENT NO. 2 
 TO THE

 PATENT AND TECHNOLOGY LICENSE AGREEMENT 

This is AMENDMENT NO. 2 effective this 8 day of August, 1997, (“EFFECTIVE AMENDMENT NO. 2 DATE”) to the Patent and Technology
License Agreement dated July 20, 1994, as amended by that certain Amendment No. 1 effective September 1, 1996 (HEREINAFTER REFERRED TO AS THE “FIRST AMENDED AGREEMENT), by and between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER
CENTER (hereinafter referred to as “MDA”), located at Houston, Texas, and which is a component institution of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter referred to as “SYSTEM”) which is governed by a BOARD OF REGENTS
(hereinafter referred to as “BOARD”) and INTROGEN THERAPEUTICS, INC., located at 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (hereinafter referred to as “LICENSEE”). 

RECITALS 
 A. BOARD is the
owner of the invention(s) and other subject matter listed in SCHEDULE B hereto (“IL-2 INVENTION(s)”). 
 B. LICENSEE is a company
interested in the development and commercialization of new technologies; directed to the treatment of cancer, and other threatening diseases, to which end LICENSEE, MDA and BOARD entered into the FIRST AMENDED AGREEMENT noted hereinabove. 

C. LICENSEE wishes to add the IL-2 INVENTIONS to the LICENSED SUBJECT MATTER under the FIRST AMENDED AGREEMENT. 

D. BOARD wishes to grant LICENSEE rights to the IL-2 INVENTIONS under the FIRST AMENDED AGREEMENT to promote its practical development for the
benefit of the MDA’s patients and for the benefit of the people of the state of Texas. 
 E. The definitions set forth in the AGREEMENT
and the FIRST AMENDED AGREEMENT shall apply in this AMENDMENT NO. 2, except to the extent that a definition herein is specific to this AMENDMENT NO. 2. 

NOW, THEREFORE, In consideration for the mutual covenants contained herein, the sufficiency of which is hereby acknowledged, the parties
hereby agree to the following: 

 The FIRST AMENDED AGREEMENT is hereby amended as follows: 

AMENDED TERMS 
 1. Add
the following as new Schedule B in its entirety; 
 SCHEDULE B 

IL-2 INVENTIONS 
 “Low
Toxicity Interleukin-2 Analogues for Use in Immunotherapy” 
 MDA. Ref. NO. UTSC 279 

Inventors: Elizabeth A. Grimm and Keith Heaton 

U.S. Patent Number: 5,229,109 Issued: July 20, 1993 

PCT Patent Number: WO/93/20849 

2. So much of Section 2.3(a) as reads 

“...the patents and patent applications described in Schedule A hereto (the “Existing Patent Rights”) and all patents anywhere
in the world issuing thereon;” 
 is hereby amended to read 

“...the patent and patent applications described in Schedules A and B hereto (the “Existing Patent Rights”) and all patents
anywhere in the world issuing thereon;” 
 3. The title for ATTACHMENT A of the AGREEMENT shall be replaced in its entirety to read as
follows: “SCHEDULE A.” 
 4. Add new paragraph 2.12 that will read in its entirety as follows: 

“2.12 IL-2 PRODUCT shall mean a LICENSED PRODUCT the manufacture, use or sale of which would infringe a VALID CLAIM within the IL-2
PATENTS.” 
 5. Add new paragraph 2.13 that will read in its entirety as follows: 

“2.13 IL-2 PATENTS shall mean those PATENT RIGHTS which claim or disclose an IL-2 INVENTION as
described in Schedule B hereto.” 
 6. Paragraph 5.1 of the AGREEMENT shall be amended by the addition of the following two new
paragraphs: 
 New 5.1(e) shall read in its entirety: 

“(e) [***] ([***]%) of NET SALES attributed to SALES of LICENSED PRODUCTS that are IL-2 PRODUCTS by LICENSEE, AFFILIATES, and
SUBLICENSEES.” For avoidance of doubt, the royalties due on PRODUCTS other than IL-2 PRODUCTS shall be as specified in Paragraph 5.1(a) above, 
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

 New 5.1(f) shall read in its entirety: 

“(f) For any advance payment attributable to an IL-2 PRODUCT or IL-2 PATENT received by LICENSEE from a third party pursuant to a
sublicensee, marketing, distribution., or franchise agreement, other than amount paid to LICENSEE in reimbursement of development or other costs, as provided for in Article 4.3 hereof and which is creditable against future royalties to be received
by LICENSEE: [***] ([***]%) of said advance payment attributable to an IL-2 PRODUCT or IL-2 PATENT.” For avoidance of doubt, advanced payments for PRODUCTS other than IL-2 PRODUCTS shall be as specified in Paragraph 5.1(b) above. 

7. The definition of TECHNOLOGY RIGHTS (Paragraph 2.4) shall be amended by the addition of the following text: 

“TECHNOLOGY RIGHTS shall also include all information, know-how, biological materials or other subject matter owned by the BOARD and
reasonably necessary for practicing an IL-2 INVENTION at any time covered by the IL-2 PATENTS,” 
 OTHERWISE, the terms and provisions
of the original AGREEMENT shall remain in full force and effect, provided, however, that in the event of a conflict in the terms and conditions between this AMENDMENT NO. 2 and the AGREEMENT, the terms and conditionals of this AMENDMENT NO. 2 shall
prevail. THIS AMENDMENT NO. 2 and the SCHEDULES hereto and the AGREEMENT and its ATTACHMENTS constitute the entire agreement between, the parties in connection with the subject matter hereof and thereof and supersede all prior and contemporaneous
agreements, understandings, negotiations and discussions, whether oral or written, of the parties. 
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  

 IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to
execute this AMENDMENT NO. 2. 
  

									
	 THE UNIVERSITY OF TEXAS
 M.D.
ANDERSON CANCER CENTER
	 		 	 BOARD OF REGENTS OF THE

UNIVERSITY OF TEXAS SYSTEM

					
	By	 	 /s/ Michael Best
	 		 	By	 	 /s/ Ray Farabee

		 	Michael J. Best	 		 		 	 Ray Farabee
 Vice Chancellor and General
Counsel

			
	APPROVED AS TO CONTENT	 		 	APPROVED AS TO FORM
					
	By:	 	 /s/ William Doty
	 		 	By:	 	 /s/ Ben Lynn Maxwell

		 	 William J. Doty
 Director, Technology
Development
	 		 		 	 Ben Lynn Maxwell, Ph.D.
 Office of
General Counsel

				
	INTROGEN THERAPEUTICS, INC.	 		 		 	
					
	By	 	 /s/ David Nance
	 		 		 	
		 	 David G. Nance
 President
	 		 		 	

 SCHEDULE B 

IL-2 INVENTIONS 
 “Low
Toxicity Interleukin-2 Analogues for Use in Immunotherapy” 
 MDA. Ref. NO. UTSC 279 

Inventors: Elizabeth A. Grimm and Keith Heaton 

U.S. Patent Number: 5,229,109 Issued: July 20, 1993 

PCT Patent Number: WO/93/20849

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]